Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial
Go back to Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial| (NYSE: IQV) | Delayed: 258.53 +1.23 (0.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $257.30 | 52 Week High | $ | |||
| Open | $258.82 | 52 Week Low | $ | |||
| Day High | $261.01 | P/E | N/A | |||
| Day Low | $257.88 | EPS | $ | |||
| Volume | 22,499 | |||||
| METABASIS THERAPEUT (NASDAQ: MBRX) | Delayed: 0.85 +0.02 (2.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.83 | 52 Week High | $9.58 | |||
| Open | $0.85 | 52 Week Low | $2.34 | |||
| Day High | $0.86 | P/E | N/A | |||
| Day Low | $0.85 | EPS | $-0.34 | |||
| Volume | 96,435 | |||||
